Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 5Prostatic Neoplasms 2Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphoma, Non-Hodgkin 1Lymphoma 1Cytokine Release Syndrome 1

Interventions

siltuximab 1otelixizumab 1fludarabine 1axicabtagene ciloleucel 1Leukapheresis 1Interleukin 1 Receptor Antagonist Protein 1Gelsolin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cytokine Release Syndrome × siltuximab × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡